ClinicalTrials.gg
CompletedNCT00767325Updated Jul 2, 2013Results posted

A Rheumatoid Arthritis Study to Assess Early Response to Abatacept+MTX as Defined by Improvement of Synovitis Measures by Power Doppler Ultrasonography

A Phase 3 interventional study of Abatacept and Methotrexate in Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb. Completed at 21 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-07-02.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
104
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 63 studies testing abatacept in Arthritis, Rheumatoid — 3 open to participants now, 4 under way, 3 of them phase 3. Abatacept · Arthritis, Rheumatoid.

Enrollment
36th of 63
104 · median 119
Started
2008
with 2 others
Phase 3
26 of 63
2 open now
Registered
21st of 63
by date
Lead sponsor
33 of 63
Bristol-Myers Squibb

Among the 63 studies testing abatacept in Arthritis, Rheumatoid, this one is the 36th largest by enrollment, is one of 3 that started in 2008, is one of 26 in phase 3, and was the 21st registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

3 of the 63 studies testing abatacept in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About abatacept

Abatacept: first FDA approval 2005 (ORENCIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing abatacept in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The purpose of the study is to assess early signs of response to abatacept+methotrexate in metacarpophalangeal joints in both hands using power Doppler ultrasonography in patients with active rheumatoid arthritis.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key inclusion riteria:

  • Disease activity defined by a disease activity score 28-C-reactive protein >3.2, or meeting the following criteria: a tender joint count ≥6; a swollen joint count ≥6; C-reactive protein measurement greater than the
  • Diagnosis of rheumatoid arthritis for longer than 6 months from time of initial diagnosis
  • Total synovitis power Doppler ultrasonography (PDUS) score >1 for at least 2 metacarpophalangeal (MCP) joints (MCP2-5) and a total synovitis PDUS score ≥1 for at least 1 other MCP joint (MCP2-5)
  • Concomitant treatment with methotrexate at a dose ≥15 mg for at least 3 months before Day 1 and a stable dose for the last 28 days before Day 1
  • No treatment with any background nonbiologic disease-modifying antirheumatic drug (DMARD) other than methotrexate for at least 28 days before treatment (Day 1)
  • Stable dose of equivalent of 10 mg prednisone /day during the 28 days prior to Day 1
  • Naive to treatment with biologic DMARDs

Key exclusion criteria:

  • Women of who are unwilling or unable to use
  • Women who are pregnant or breastfeeding
  • Meeting all diagnostic criteria for any other rheumatic disease
  • Previous MCP arthroplasty, with such a procedure scheduled, or anticipating the need for such a procedure during the study. Participants who had undergone or were scheduled to undergo joint arthroplasties other than of the MCP joints were permitted to enroll in the study provided all other eligibility criteria were met.
  • Active vasculitis of a major organ system with the exception of rheumatoid nodule
  • Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematologic, gastrointestinal, pulmonary, cardiac, neurologic, or cerebral disease, whether or not related to rheumatoid arthritis
  • History of cancer in the last 5 years, other than nonmelanoma skin cell cancer cured by local resection or carcinoma in situ. Existing nonmelanoma skin cell cancers should have been removed, the lesion site healed, and residual cancer ruled out prior to administration of study medication
  • abuse of alcohol or drugs
  • Evidence of active or latent bacterial or viral infections at the time of potential enrollment
  • Herpes zoster or cytomegalovirus infection that resolved less than 2 months before the document was signed
  • For participants at risk for tuberculosis (TB):

    • A history of active (TB) within the last 3 years, even if treated
    • Latent TB that was not successfully treated ≥4 weeks
    • Current clinical, radiographic, or laboratory evidence of active TB.
  • Participants who have received within 3 months of the anticipated first dose of study medication
  • Participants with positive test results for surface antigen or antibody, with hepatitis C virus detected with polymerase chain reaction or recombinant immunoblot assay.
  • Participants with level \<8.5 g/dL or white blood cell count\< 3000/mm\^3 or count \<100,000/mm\^3 or serum creatinin level >2*the upper limit of normal (ULN) or serum level or aspartate aminotransferase level >2*ULN
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
104 participants (actual)

Study arms

  • Experimental
    Abatacept, 10 mg/kg

    Drug: Abatacept · Drug: Methotrexate

Interventions

  • Abatacept, 10 mg/kg, solution given intravenously on Days 1, 15, 29,57, 85, 113, 141, and 169

    Also known as: Orencia®, BMS-188667

  • Methotrexate administered in a dose of 15 mg/week or higher for at least 3 months and at a stable dose for at least 28 days prior to baseline

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Global Power Doppler Ultrasonography (PDUS) Score Assessing the Metacarpophalangeal (MCP) 2-5 Joints of Both Hands (LOCF Analysis)

    LOCF=last observation carried forward. PDUS assessed the degree of synovial inflammation of the MCP joints (2nd to 5th) of both hands and was performed at approximately the same time of day for each participant. Total PDUS scores are independent of the presence and grade of joint effusion and are evaluated as follows: Grade 0 or normal=normal joint (no synovial hypertrophy, no Doppler signal); Grade 1 or minimal=minimal synovitis (minimal synovial hypertrophy, with ≤Grade 1 Doppler signal); Grade 2 or moderate=moderate synovitis (moderate synovial hypertrophy with ≤Grade 2 Doppler signal or minimal synovial hypertrophy and Grade 2 Doppler signal; Grade 3 or severe=severe synovitis (severe synovial hypertrophy with ≤Grade 3 Doppler signal or minimal or moderate synovial hypertrophy and Grade 3 Doppler signal). Each joint is rated 1 to 3, for a total possible score ranging from 8 to 24 (8\*1, 8\*3) for 2 hands. Higher grade/score=more severe disease. Change=score Day x - baseline score.

    Time frame: Baseline to Days 7, 15, 29, 43, 57, 85, 113, 141, and 169

  2. Earliest Time Point at Which Improvement of Core Component of the Global PDUS in the MCP (2-5) Joints of Both Hands Was Assessed

    MCP=metacarpophalangeal; PDUS=power Doppler ultrasonography. Time point at which early signs of Global PDUS improvement were observed=earliest time point for which 0 was not included in the 95% confidence interval for the mean changes from baseline in Global PDUS (MCP 2-5) score at that and all later time points. Total PDUS scores are independent of the presence and grade of joint effusion: Grade (Gr) 0 or normal=normal joint (no synovial hypertrophy \[SH\], no Doppler signal); Gr 1 or minimal=minimal synovitis (minimal SH, with ≤Gr 1 Doppler signal); Gr 2 or moderate=moderate synovitis (moderate SH, with ≤Gr 2 Doppler signal or minimal SH and grade 2 Doppler signal); Gr 3 or severe=severe synovitis (severe SH with ≤Gr 3 Doppler signal or minimal or moderate SH and Gr 3 Doppler signal). Each joint is rated 1 to 3, for a total possible score ranging from 8 to 24 (8\*1, 8\*3) for the 2 hands. Higher Gr/score=more severe disease.

    Time frame: Baseline to Days 7, 15, 29, 43, 57, 85, 113, 141, and 169

Secondary outcomes

  1. Mean Change From Baseline in Global PDUS MCP 2-5 Component Scores Over Time (LOCF Analysis)

    PDUS=power Doppler ultrasonography; MCP=metacarpophalangeal; LOCF=last observation carried forward. PDUS was used to assess the degree of synovial inflammation of the MCP joints (2nd to 5th) of both hands and was performed at approximately the same time of day for each participant. PDUS scores are independent of the presence and grade of joint effusion and are evaluated as follows: Grade 0 or normal=normal joint (no synovial hypertrophy, no Doppler signal); Grade 1 or minimal=minimal synovitis (minimal synovial hypertrophy, with ≤Grade 1 Doppler signal); Grade 2 or moderate=moderate synovitis (moderate synovial hypertrophy with ≤Grade 2 Doppler signal or minimal synovial hypertrophy and grade 2 Doppler signal); Grade 3 or severe=severe synovitis (severe synovial hypertrophy with ≤ Grade 3 Doppler signal or minimal or 1-3, for a total possible score ranging from 8 to 24 (8\*1, 8\*3) for the 2 hands. Higher grade/score=more severe disease. Change=score Day X-baseline score.

    Time frame: Days 7, 15, 29, and 169

  2. Number of Early (Days 7 to 113) Global PDUS MCP 2-5 Scores or Global PDUS Component MCP 2-5 Scores Associated With an Acceptable Predictability of Clinical Response at Day 169, As Assessed by DAS28-CRP

    MCP=metacarpophalangeal; PDUS=power Doppler ultrasonography; DAS=Disease Activity Score;CRP=C-reactive protein. Receiver Operator Characteristics (ROC) analysis assessed predicatability. ROC curve analyses performed; area under the curve of ≥0.7 was considered acceptable for prediction. Clinical response defined as: Clinically Meaningful Improvement=drop from baseline of ≥1.2 in DAS28-CRP; Remission=DAS28-CRP score \<2.6; Low Disease Activity=≤3.2. PDUS scores: Grade (Gr) 0 or normal=normal joint (no synovial hypertrophy \[SH\], no Doppler signal); Gr 1 or minimal=minimal synovitis (minimal SH, with ≤Gr 1 Doppler signal); Gr 2 or moderate=moderate synovitis (moderate SH with ≤Gr 2 Doppler signal or minimal SH and Gr 2 Doppler signal); Gr 3 or severe=severe synovitis (severe SH with ≤Gr 3 Doppler signal or minimal or moderate SH and Gr 3 Doppler signal). Each joint rated 1-3, for a total possible score ranging from 8-24 (8\*1, 8\*3)for the 2 hands. Higher gr/score=more severe disease.

    Time frame: Days 1 to 169

  3. Number of Participants With Death as Outcome, Serious Adverse Events(SAEs), Treatment-related SAEs, Discontinuations Due to SAEs, Adverse Events (AEs), Treatment-related AEs, Discontinuations Due to AEs

    AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug.

    Time frame: Days 1 to 169 to 56 days following last infusion

  4. Number of Participants With Adverse Events (AEs) of Interest

    AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. Infusion reaction: acute=1 hour or less after start of dosing; periinfusional=24 hours or less after start of dosing.

    Time frame: Days 1 to 169 to 56 days following last infusion

07

Results

Posted Jun 21, 2013
Limitations and caveats
Power Doppler ultrasonography values from 1 site (8 participants were excluded due to technical and quality issues with PDUS scoring and compliance issues.)

Participant flow

Participant flow — Overall Study
MilestoneAbatacept, 10 mg/kg
Started104
Completed89
Not completed15
Withdrew: Lack of efficacy2
Withdrew: Adverse event7
Withdrew: Lost to follow-up3
Withdrew: No longer met study criteria2
Withdrew: Missed visit due to family reasons1

Outcome measures

PrimaryMean Change From Baseline in Global Power Doppler Ultrasonography (PDUS) Score Assessing the Metacarpophalangeal (MCP) 2-5 Joints of Both Hands (LOCF Analysis)

LOCF=last observation carried forward. PDUS assessed the degree of synovial inflammation of the MCP joints (2nd to 5th) of both hands and was performed at approximately the same time of day for each participant. Total PDUS scores are independent of the presence and grade of joint effusion and are evaluated as follows: Grade 0 or normal=normal joint (no synovial hypertrophy, no Doppler signal); Grade 1 or minimal=minimal synovitis (minimal synovial hypertrophy, with ≤Grade 1 Doppler signal); Grade 2 or moderate=moderate synovitis (moderate synovial hypertrophy with ≤Grade 2 Doppler signal or minimal synovial hypertrophy and Grade 2 Doppler signal; Grade 3 or severe=severe synovitis (severe synovial hypertrophy with ≤Grade 3 Doppler signal or minimal or moderate synovial hypertrophy and Grade 3 Doppler signal). Each joint is rated 1 to 3, for a total possible score ranging from 8 to 24 (8\*1, 8\*3) for 2 hands. Higher grade/score=more severe disease. Change=score Day x - baseline score.

Time frame:
Baseline to Days 7, 15, 29, 43, 57, 85, 113, 141, and 169
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Global Power Doppler Ultrasonography (PDUS) Score Assessing the Metacarpophalangeal (MCP) 2-5 Joints of Both Hands (LOCF Analysis)
Units on a scaleAbatacept, 10 mg/kg
Day 7 (n=86)-0.7 ± 0.282
Day 15 (n=94)-1.3 ± 0.308
Day 29 (n=95)-2.4 ± 0.383
Day 43 (n=95)-2.9 ± 0.384
Day 57 (n=95)-3.2 ± 0.393
Day 85 (n=95)-3.8 ± 0.454
Day 113 (n=95)-4.5 ± 0.472
Day 141 (n=95)-4.8 ± 0.492
Day 169 (n=95)-4.8 ± 0.473
Statistical analysis
  • Abatacept, 10 mg/kg · Mean difference (final values): -0.7 · 95% CI -1.2 to -0.1Day 7
  • Abatacept, 10 mg/kg · Mean difference (final values): -1.3 · 95% CI -2.0 to -0.7Day 15
  • Abatacept, 10 mg/kg · Mean difference (final values): -2.4 · 95% CI -3.2 to -1.7Day 29
  • Abatacept, 10 mg/kg · Mean difference (final values): -2.9 · 95% CI -3.7 to -2.1Day 43
  • Abatacept, 10 mg/kg · Mean difference (final values): -3.2 · 95% CI -4.0 to -2.4Day 57
  • Abatacept, 10 mg/kg · Mean difference (final values): -3.8 · 95% CI -4.7 to -2.9Day 85
  • Abatacept, 10 mg/kg · Mean difference (final values): -4.5 · 95% CI -5.4 to -3.5Day 113
  • Abatacept, 10 mg/kg · Mean difference (final values): -4.8 · 95% CI -5.8 to -3.8Day 141
  • Abatacept, 10 mg/kg · Mean difference (final values): -4.8 · 95% CI -5.8 to -3.9Day 169
SecondaryMean Change From Baseline in Global PDUS MCP 2-5 Component Scores Over Time (LOCF Analysis)

PDUS=power Doppler ultrasonography; MCP=metacarpophalangeal; LOCF=last observation carried forward. PDUS was used to assess the degree of synovial inflammation of the MCP joints (2nd to 5th) of both hands and was performed at approximately the same time of day for each participant. PDUS scores are independent of the presence and grade of joint effusion and are evaluated as follows: Grade 0 or normal=normal joint (no synovial hypertrophy, no Doppler signal); Grade 1 or minimal=minimal synovitis (minimal synovial hypertrophy, with ≤Grade 1 Doppler signal); Grade 2 or moderate=moderate synovitis (moderate synovial hypertrophy with ≤Grade 2 Doppler signal or minimal synovial hypertrophy and grade 2 Doppler signal); Grade 3 or severe=severe synovitis (severe synovial hypertrophy with ≤ Grade 3 Doppler signal or minimal or 1-3, for a total possible score ranging from 8 to 24 (8\*1, 8\*3) for the 2 hands. Higher grade/score=more severe disease. Change=score Day X-baseline score.

Time frame:
Days 7, 15, 29, and 169
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Global PDUS MCP 2-5 Component Scores Over Time (LOCF Analysis)
Units on a scaleAbatacept, 10 mg/kg
Synovial hypertrophy (n=86): Day 7-0.6 ± 0.297
Synovial hypertrophy (n=94): Day 15-1.0 ± 0.306
Synovial hypertrophy (n=95): Day 29-2.1 ± 0.377
Synovial hypertrophy (n=95): Day 169-4.5 ± 0.449
Doppler signal: Day 7 (n=86)-0.9 ± 0.305
Doppler signal: Day 15 (n=94)-1.9 ± 0.296
Doppler signal: Day 29 (n=95)-2.2 ± 0.350
Doppler signal: Day 169 (n=95)-4.8 ± 0.457
Joint effusion: Day 7 (n=86)0.1 ± 0.237
Joint effusion: Day 15 (n=94)0.1 ± 0.243
Joint effusion: Day 29 (n=95)-0.8 ± 0.294
Joint effusion: Day 169 (n=95)-1.9 ± 0.351
PrimaryEarliest Time Point at Which Improvement of Core Component of the Global PDUS in the MCP (2-5) Joints of Both Hands Was Assessed

MCP=metacarpophalangeal; PDUS=power Doppler ultrasonography. Time point at which early signs of Global PDUS improvement were observed=earliest time point for which 0 was not included in the 95% confidence interval for the mean changes from baseline in Global PDUS (MCP 2-5) score at that and all later time points. Total PDUS scores are independent of the presence and grade of joint effusion: Grade (Gr) 0 or normal=normal joint (no synovial hypertrophy \[SH\], no Doppler signal); Gr 1 or minimal=minimal synovitis (minimal SH, with ≤Gr 1 Doppler signal); Gr 2 or moderate=moderate synovitis (moderate SH, with ≤Gr 2 Doppler signal or minimal SH and grade 2 Doppler signal); Gr 3 or severe=severe synovitis (severe SH with ≤Gr 3 Doppler signal or minimal or moderate SH and Gr 3 Doppler signal). Each joint is rated 1 to 3, for a total possible score ranging from 8 to 24 (8\*1, 8\*3) for the 2 hands. Higher Gr/score=more severe disease.

Time frame:
Baseline to Days 7, 15, 29, 43, 57, 85, 113, 141, and 169
Reported as:
Number · Day
Earliest Time Point at Which Improvement of Core Component of the Global PDUS in the MCP (2-5) Joints of Both Hands Was Assessed
DayAbatacept, 10 mg/kg
Earliest Time Point at Which Improvement of Core Component of the Global PDUS in the MCP (2-5) Joints of Both Hands Was Assessed7 (-1.5 to -0.3)
SecondaryNumber of Early (Days 7 to 113) Global PDUS MCP 2-5 Scores or Global PDUS Component MCP 2-5 Scores Associated With an Acceptable Predictability of Clinical Response at Day 169, As Assessed by DAS28-CRP

MCP=metacarpophalangeal; PDUS=power Doppler ultrasonography; DAS=Disease Activity Score;CRP=C-reactive protein. Receiver Operator Characteristics (ROC) analysis assessed predicatability. ROC curve analyses performed; area under the curve of ≥0.7 was considered acceptable for prediction. Clinical response defined as: Clinically Meaningful Improvement=drop from baseline of ≥1.2 in DAS28-CRP; Remission=DAS28-CRP score \<2.6; Low Disease Activity=≤3.2. PDUS scores: Grade (Gr) 0 or normal=normal joint (no synovial hypertrophy \[SH\], no Doppler signal); Gr 1 or minimal=minimal synovitis (minimal SH, with ≤Gr 1 Doppler signal); Gr 2 or moderate=moderate synovitis (moderate SH with ≤Gr 2 Doppler signal or minimal SH and Gr 2 Doppler signal); Gr 3 or severe=severe synovitis (severe SH with ≤Gr 3 Doppler signal or minimal or moderate SH and Gr 3 Doppler signal). Each joint rated 1-3, for a total possible score ranging from 8-24 (8\*1, 8\*3)for the 2 hands. Higher gr/score=more severe disease.

Time frame:
Days 1 to 169
Reported as:
Number · Scores
Number of Early (Days 7 to 113) Global PDUS MCP 2-5 Scores or Global PDUS Component MCP 2-5 Scores Associated With an Acceptable Predictability of Clinical Response at Day 169, As Assessed by DAS28-CRP
ScoresAbatacept, 10 mg/kg
Clinically meaningful improvement0
Remission0
Low disease activity0
SecondaryNumber of Participants With Death as Outcome, Serious Adverse Events(SAEs), Treatment-related SAEs, Discontinuations Due to SAEs, Adverse Events (AEs), Treatment-related AEs, Discontinuations Due to AEs

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug.

Time frame:
Days 1 to 169 to 56 days following last infusion
Reported as:
Number · Participants
Number of Participants With Death as Outcome, Serious Adverse Events(SAEs), Treatment-related SAEs, Discontinuations Due to SAEs, Adverse Events (AEs), Treatment-related AEs, Discontinuations Due to AEs
ParticipantsAbatacept, 10 mg/kg
Deaths0
SAEs6
Treatment-related SAEs2
Discontinuations due to SAEs1
AEs62
Treatment-related AEs22
Discontinuations due to AEs6
SecondaryNumber of Participants With Adverse Events (AEs) of Interest

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. Infusion reaction: acute=1 hour or less after start of dosing; periinfusional=24 hours or less after start of dosing.

Time frame:
Days 1 to 169 to 56 days following last infusion
Reported as:
Number · Participants
Number of Participants With Adverse Events (AEs) of Interest
ParticipantsAbatacept, 10 mg/kg
Infections20
Malignancy1
Autoimmune disorders (prespecified)2
Infusion reactions (prespecified): Acute4
Infusion reactions (prespecified): Periinfusional10

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aba 10 mg/kg—6/104 (5.8%)15/104 (14.4%)
Most frequent serious events
Most frequent serious events
EventAba 10 mg/kg
Atrial fibrillationCardiac disorders1/104
Bursitis infectiveInfections and infestations1/104
Pulmonary fistulaRespiratory, thoracic and mediastinal disorders1/104
DementiaNervous system disorders1/104
EndometriosisReproductive system and breast disorders1/104
HypertensionVascular disorders1/104
Pleural effusionRespiratory, thoracic and mediastinal disorders1/104
Most frequent other events
Most frequent other events
EventAba 10 mg/kg
CoughRespiratory, thoracic and mediastinal disorders9/104
NasopharyngitisInfections and infestations7/104

Baseline characteristics

Age Continuous
Age Continuous(Years)Abatacept, 10 mg/kg
Mean56.4 ± 14.1
Sex: Female, Male
Sex: Female, Male(Participants)Abatacept, 10 mg/kg
Female87
Male17
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Abatacept, 10 mg/kg
American Indian or Alaska Native1
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American0
White101
Other1
Tender joint count
Tender joint count(Joints)Abatacept, 10 mg/kg
Mean19.5 ± 12.5
Duration of rheumatoid arthritis
Duration of rheumatoid arthritis(Years)Abatacept, 10 mg/kg
Mean7.3 ± 9.1
Swollen joint count
Swollen joint count(Joints)Abatacept, 10 mg/kg
Mean13.0 ± 7.6
DAS 28-CRP score
DAS 28-CRP score(Units on a scale)Abatacept, 10 mg/kg
Mean5.2888 ± 1.105
Global PDUS (MCP 2-5) score (n=96)
Global PDUS (MCP 2-5) score (n=96)(Units on a scale)Abatacept, 10 mg/kg
Mean12.6 ± 4.1
08

Study locations

21 sites
  • Local Institution
    Glostrup, DK-2600, Denmark
  • Local Institution
    Bois Guillaume Cedex, 76230, France
  • Local Institution
    Boulogne, 92104, France
  • Local Institution
    Echirolles, 38434, France
  • Local Institution
    Nice Cedex 03, 06202, France
  • Local Institution
    Munchen, 80639, Germany
  • Local Institution
    Budapest, 1036, Hungary
  • Local Institution
    Jesi (Ancona), 60035, Italy
  • Local Institution
    Pisa, 56126, Italy
  • Local Institution
    Roma, 00161, Italy
  • Local Institution
    Roma, 00168, Italy
  • Local Institution
    Siena, 53100, Italy
  • Local Institution
    Verona, 37126, Italy
  • Local Institution
    Oslo, N0319, Norway
  • Local Institution
    Trondheim, 7006, Norway
  • Local Institution
    Barcelona, 08006, Spain
  • Local Institution
    Madrid, 28006, Spain
  • Local Institution
    Madrid, 28040, Spain
  • Local Institution
    Madrid, 28911, Spain
  • Local Institution
    Madrid, 28935, Spain
  • Local Institution
    Leeds, North Yorkshire LS7 4SA, United Kingdom
09

References and documents

Publications

  • D'Agostino MA, Boers M, Wakefield RJ, Berner Hammer H, Vittecoq O, Filippou G, Balint P, Moller I, Iagnocco A, Naredo E, Ostergaard M, Gaillez C, Le Bars M. Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: results from the APPRAISE study. RMD Open. 2016 May 5;2(1):e000237. doi: 10.1136/rmdopen-2015-000237. eCollection 2016. PubMed 27175297 ↗
  • Golinski ML, Vandhuick T, Derambure C, Freret M, Lecuyer M, Guillou C, Hiron M, Boyer O, Le Loet X, Vittecoq O, Lequerre T. Dysregulation of RasGRP1 in rheumatoid arthritis and modulation of RasGRP3 as a biomarker of TNFalpha inhibitors. Arthritis Res Ther. 2015 Dec 26;17:382. doi: 10.1186/s13075-015-0894-9. PubMed 26714738 ↗
  • D'Agostino MA, Wakefield RJ, Berner-Hammer H, Vittecoq O, Filippou G, Balint P, Moller I, Iagnocco A, Naredo E, Ostergaard M, Boers M, Gaillez C, Van Holder K, Le Bars M; OMERACT-EULAR-Ultrasound Task Force. Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results from the APPRAISE study. Ann Rheum Dis. 2016 Oct;75(10):1763-9. doi: 10.1136/annrheumdis-2015-207709. Epub 2015 Nov 20. PubMed 26590174 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2008, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2013, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2008
First posted
Oct 7, 2008
Start
Dec 2008
Primary completionActual
Oct 2011
CompletionActual
Oct 2011
Results first posted
Jun 21, 2013
Last update
Jul 2, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00767325
Responsible party
Sponsor
First posted
Oct 7, 2008
Start date
Dec 2008
Primary completion
Oct 2011
Completion
Oct 2011
Results posted
Jun 21, 2013
Last update
Jul 2, 2013

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Abatacept · Methotrexate

Start the discussion